March 5, 2018 07:54 AM EST
R&D

San­thera’s Rax­one fails NIH’s MS study in lat­est set­back, shares plunge

John Carroll

Editor & Founder

Just a few weeks af­ter be­ing shot down (again) by Eu­ro­pean reg­u­la­tors who were op­posed to let­ting San­thera (SIX: SANN) ex­tend its mar­ket­ing ap­proval for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times